Sagent Pharmaceuticals

Sagent Pharmaceuticals
Public
Traded as NASDAQ: SGNT
Industry Biotechnology
Key people

Allan Oberman (CEO)[1]

Jonathon Singer (CFO)
Revenue $318 million
$23 million
Website sagentpharma.com

Sagent Pharmaceuticals is a biopharmaceutical company founded in 2007. The company received series A funding of $53 million,[2] as well as $40 million in two rounds of series B funding.[3] As part of the funding, Zhejiang Hisun Pharmaceutical Co. Ltd made an investment of $10 million in Sagent. In total, the company has raised $153 million in equity capital.[3] In 2011 the company filed for IPO - offering 5,750,000 shares of common stock at a price to the public of $16 per share[4]

The company was acquired by Nichi-Iko Pharmaceutical Co., Ltd in 2016.

Company history

In 2010, the company entered a partnership with Actavis to market and supply a number of injectable products.[5]

In 2014, the company announced its intention to acquire Omega Laboratories Limited for $85.3 million[6]

In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.[7]

In 2016, the company made its most notable acquisition to date, when it acquired five Abbreviated New Drug Applications from Teva Pharmaceuticals for $40 million. As part of Teva's acquisition on Actavis Generics, a number of drug portfolios are being sold off.[8] Later in the same year, the company was acquired by Nichi-Iko Pharmaceutical Co., Ltd for $736 million[9][10] (representing $21.75 per share and a 40% share premium).[11][12][13]

References

  1. ↑ "Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer (NASDAQ:SGNT)".
  2. ↑ "Sagent Pharmaceuticals, Inc. completes $53 million series a financing (NASDAQ:SGNT)".
  3. 1 2 "Sagent Pharmaceuticals raises $40 million in two tranches of a series B financing (NASDAQ:SGNT)".
  4. ↑ "Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering (NASDAQ:SGNT)".
  5. ↑ "Sagent Pharmaceuticals and Actavis enter into exclusive U.S. development, supply and marketing collaboration for a portfolio of specialty injectable pharmaceutical products (NASDAQ:SGNT)".
  6. ↑ "Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories (NASDAQ:SGNT)".
  7. ↑ "Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results (NASDAQ:SGNT)".
  8. ↑ "Sagent Buys Five ANDAs, Including Propofol, from Teva for $40M - GEN News Highlights - GEN".
  9. ↑ "Nichi-Iko to Acquire Sagent Pharmaceuticals for $736M - GEN News Highlights - GEN".
  10. ↑ Jamerson, Joshua (11 July 2016). "Nichi-Iko Pharmaceutical to Buy Sagent Pharmaceuticals in $736 Million Deal" – via Wall Street Journal.
  11. ↑ "Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction (NASDAQ:SGNT)".
  12. ↑ Jr, Berkeley Lovelace (11 July 2016). "Sagent Pharmaceuticals shares on Nichi-Iko's tender offer".
  13. ↑ "Japanese drugmaker buying Sagent to get U.S. beachhead - FiercePharma".
This article is issued from Wikipedia - version of the 9/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.